Immunic (NASDAQ:IMUX) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
Risk & Volatility
Immunic has a beta of 3.69, suggesting that its share price is 269% more volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
This table compares Immunic and Seelos Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and recommmendations for Immunic and Seelos Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Immunic presently has a consensus price target of $40.00, suggesting a potential upside of 228.14%. Seelos Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 229.67%. Given Seelos Therapeutics’ higher possible upside, analysts clearly believe Seelos Therapeutics is more favorable than Immunic.
Earnings & Valuation
This table compares Immunic and Seelos Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Seelos Therapeutics||$5.76 million||6.72||-$9.24 million||N/A||N/A|
Seelos Therapeutics has higher revenue and earnings than Immunic.
Institutional & Insider Ownership
5.1% of Seelos Therapeutics shares are owned by institutional investors. 67.9% of Immunic shares are owned by insiders. Comparatively, 15.5% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Seelos Therapeutics beats Immunic on 5 of the 9 factors compared between the two stocks.
Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.
About Seelos Therapeutics
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.